Faculty of Theology, Old University of Leuven

Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis

Retrieved on: 
Tuesday, November 22, 2022
Issuer, Allergen, TRPV1, Network congestion, European Forum of Medical Associations, Euronext, University, Rhinorrhea, Pain, Allergic rhinitis, Overalls, Patient, Sensation, Sleep, Sneeze, Research, Thermoregulation, Webcast, Education, Rhinitis, Information, Faculty of Theology, Old University of Leuven, CET, Nociception, Nasal mucosa, Collection, Quality of life, Transient receptor potential channel, Frustration, Irritability, Atrial fibrillation, Microsoft, Safety, Pharmaceutical industry, Vaccine, Allergy

Idiopathic rhinitis is a medical disorder characterized by a collection of nasal symptoms that resemble nasal allergies and hay fever (allergic rhinitis) but are not caused by a known cause like allergens or infectious triggers.

Key Points: 
  • Idiopathic rhinitis is a medical disorder characterized by a collection of nasal symptoms that resemble nasal allergies and hay fever (allergic rhinitis) but are not caused by a known cause like allergens or infectious triggers.
  • Idiopathic rhinitis features an overexpression of TRPV1 in the nasal mucosa giving rise to nasal obstruction, rhinorrhoea (colloquially: a runny nose), and/or sneezing.
  • Hyloris treatment approach is to activate and depolarize TRPV1 receptors leading to restoration of a normal function of the nasal mucosa.
  • Stijn Van Rompay, Chief Executive Officer of Hyloris,commented: We are pleased to announce another value-added product candidate to add to our portfolio of programs.

reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a

Retrieved on: 
Tuesday, May 3, 2022
Neurodegeneration, Medical University of Vienna, Neuron, Epilepsy, Alzheimer's disease, AD, University, NV, Brain, Cerebrospinal fluid, Contract research organization, Pharmacokinetics, CNS, Plasma protein binding, Government budget balance, Safety, Cognition, CSF, Central nervous system disease, Patient, Amyloid, Risk, Clinical trial, Animal, Program, Inflammation, CRO, Hippocampus, Amnesia, Faculty of Theology, Old University of Leuven, Disease, ALS, Medical school, Pharmaceutical industry, Vaccine

reMYNDs novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a

Key Points: 
  • reMYNDs novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a
    Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage company tackling neurodegeneration, today announces that its lead Alzheimer program ReS19-T has successfully completed its Phase 1 study.
  • Topline data has demonstrated excellent brain exposure and strong safety profile.
  • These results support the next phase of clinical development, a Phase 2a proof-of-mechanism study slated for initiation soon.
  • reMYNDs most advanced program is ReS19-T, an investigational compound for the treatment of Alzheimers and ready to start Phase 2a.

reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase

Retrieved on: 
Thursday, October 21, 2021
UNLV, Safety, SAD, MAD, Phase, Central nervous system disease, Volunteering, University, Disease, Human, CNS, NV, Patient, Insulin, Medical University of Vienna, Calcium, Learning, Food, Cognition, CRO, Clinical trial, Pharmacokinetics, Diabetes, Degenerative disease, Central nervous system, Contract research organization, Faculty of Theology, Old University of Leuven, Amnesia, Medical school, Pharmaceutical industry

The multiple-ascending dose (MAD) phase has been initiated well before the maximum tolerable dose has been reached.

Key Points: 
  • The multiple-ascending dose (MAD) phase has been initiated well before the maximum tolerable dose has been reached.
  • To date, healthy volunteers in the SAD phase have been dosed up to 700 mg, and food impact has been assessed at this high dose.
  • The preclinical studies and early clinical trials of ReS19-T provide a strong foundation for advancing this innovative treatment.
  • With this promising data we are getting close to a pivotal test of the calcium hypothesis in patients in 2022.